No 2 (2014)
MAMMOLOGY. TOPICAL ISSUE
Genotype-phenotype correlations in patients with breast cancer and BRCA1 mutations (4153delA, 185delAG, 5382insC)
Abstract
8-11
Breast sarcomas. Literature review
Abstract
12-15
5-PGDH expression in breast cancer cells
Abstract
16-22
MAMMOLOGY. CLINICAL OBSERVATIONS
Clinical and morphological parallels in the diagnosis of squamous cell carcinoma of the breast: a description of a clinical case
Abstract
41-44
MAMMOLOGY. TREATMENT
Radiotherapy following organ-sparing surgery for breast cancer
Abstract
The paper gives a major update on the most optimal use of radiotherapy following breast-sparing surgery. It discusses indications for and contraindications to the technique in different age categories and in different prognostic factors.
23-29
Neoadjuvant treatment for breast cancer
Abstract
30-36
Comprehensive analysis of the factors affecting the duration of the existence of subcutaneous seroma after surgical treatment of breast cancer patients
Abstract
37-40
MAMMOLOGY. PRECANCEROUS PATHOLOGY
Practical guidelines for drug correction of diffuse dyshormonal dysplasia of the breast
Abstract
45-52
GYNECOLOGY. DIAGNOSIS
Clinical and diagnostic value of the functional and conformational properties of serum albumin in patients with ovarian cancer (а pilot study)
Abstract
59-61
GYNECOLOGY. TREATMENT
Clinical guidelines for the treatment of patients with vulvar squamous cell carcinoma with consideration for the FIGO (2009) and TNM (2010) classifications
Abstract
62-67
Clinical case use bevacizumab for patient with metastatic ovarian cancer
Abstract
High incidence and mortality rate for ovarian cancer patients, short-term survival until relapse, repeated following surgeries and chemo- therapy, and also low survival rates make the problem of treatment of this pathology vital. Nowadays combination of platinum and paclitaxel (gemcitabine) in addition with targeted therapy (bevacizumab) is the most effective chemotherapy for first and second line of stages III and IV ovarians cancer. Considering high efficacy of these combinations aimed at the improving of the results of survival, further study of the use of bevacizumab in metastatic ovarian cancer therapy is necessary.
М.Р. Оганян, О.В. Давиденко
ГБУЗ «Клинический онкологический диспансер No 1» Минздрава Краснодарского края, Краснодар Контакты: Мариэтта Рафаэловна Оганян kapurol@mail.ru
68-72
GYNECOLOGY. REGIONAL EXPERIENCE
The Republican Oncology Dispensary’s experience in treating malignant trophoblastic tumors: ways of improvement
Abstract
73-78
GYNECOLOGY. PROBLEM
Borderline ovarian tumors: а modern view of the problem
Abstract
53-55
56-58




